Prostate epithelial AR inactivation leads to increased intraprostatic androgen synthesis

Prostate

Volumn 73, Issue 3, 2013, Pages 316-327

  McNamara, Keely M ^a,b   Nakamura, Yasuhiro ^b   Sasano, Hironobu ^b   Handelsman, David J ^a   Simanainen, Ulla ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 R2; androgen independence; AR; PEARKO mice; prostate

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; TESTOSTERONE;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASTRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STEROID ANALYSIS; STROMA CELL; WILD TYPE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ANDROGENS; ANIMALS; DIHYDROTESTOSTERONE; ESTRADIOL; GENE SILENCING; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PROSTATE; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 84872815304     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22570     Document Type: Article

References (54)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G,. The worldwide epidemiology of prostate cancer: Perspectives from autopsy studies. Can J Urol 2008; 15 (1): 3866-3871.
2. Martin RM,. Commentary: Prostate cancer is omnipresent, but should we screen for it ? Int J Epidemiol 2007; 36 (2): 278-281.
3. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD,. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30 (2): 138-144.
4. Bonkhoff H, Stein U, Aumuller G, Remberger K,. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996; 29 (4): 261-267.
5. Nishiyama T,. Intra-prostatic androgen levels during various androgen-blockade regimens. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 229-241.
6. Mostaghel EA, Nelson PS,. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 243-258.
7. Pelletier G, Luu-The V, Li S, Ouellet J, Labrie F,. Cellular localization of mRNA expression of enzymes involved in the formation and inactivation of hormonal steroids in the mouse prostate. J Histochem Cytochem 2004; 52 (10): 1351-1356.
8. Marks LS,. 5alpha-reductase: History and clinical importance. Rev Urol 2004; 6 (Suppl 9): S11-S21.
9. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H,. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008; 99 (1): 81-86.
10. Levine AC, Wang JP, Ren M, Eliashvili E, Russell DW, Kirschenbaum A,. Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 1996; 81 (1): 384-389.
11. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100 (3): 170-183.
12. Jin Y, Penning TM,. Steroid 5 alpha-reductases and 3 alpha hydroxysteroid dehydrogenases: Key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metabol 2001; 15 (1): 79-94.
13. Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI,. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol 1998; 186 (2): 169-177.
14. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F,. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: Potential implications for prostate cancer development and prognosis. BJU Int 2008; 101 (10): 1302-1309.
15. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61 (11): 4315-4319.
16. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ,. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53 (2): 244-252.
17. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108 (33): 13728-13733.
18. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM,. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011; 71 (4): 1486-1496.
19. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68 (15): 6407-6415.
20. George FW, Russell DW, Wilson JD,. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci USA 1991; 88 (18): 8044-8047.
21. Normington K, Russell DW,. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 1992; 267 (27): 19548-19554.
22. Yamashita S,. Localization of estrogen and androgen receptors in male reproductive tissues of mice and rats. Anat Rec A Discov Mol Cell Evol Biol 2004; 279 (2): 768-778.
23. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, Zajac JD, Davey RA, Handelsman DJ,. Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 2007; 148 (5): 2264-2272.
24. Simanainen U, McNamara K, Gao YR, Handelsman DJ,. Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation. Am J Physiol Endocrinol Metab 2009; 296 (6): E1335-E1343.
25. Simanainen U, McNamara K, Gao YR, McPherson S, Desai R, Jimenez M, Handelsman DJ,. Anterior prostate epithelial AR inactivation modifies estrogen receptor expression and increases estrogen sensitivity. Am J Physiol Endocrinol Metab 2011; 301 (4): E727-E735.
26. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, Cunha GR,. Steroid hormones stimulate prostate cancer progression and metastasis. Int J Cancer 2006; 118 (9): 2123-2131.
27. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR,. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000; 60 (21): 6008-6017.
28. Jimemez M, Jones M, McPherson SJ, Risbridger GP, Spaliviero J, Allan CM, Handelsman D,. Effects of low dose estradiol silastic implants in aromatase deficient (ArKO) mice Proceedings, Endocrine Society of Australia, 2005.
29. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD,. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64 (6): 2270-2305.
30. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Wang L, Chan MS, Wing L, Yiu CC, Chow LW, Sasano H,. Increased 5alpha-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: The correlation with decreased tumor cell proliferation. Horm Cancer 2011; 2 (1): 73-81.
31. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H,. 5α-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 2007; 120 (2): 285-291.
32. McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M, Handelsman DJ,. Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography tandem mass spectrometry. J Steroid Biochem Mol Biol 2010; 121 (3-5): 611-618.
33. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS,. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998; 58 (24): 5718-5724.
34. Lundmo PI, Sunde A, Tveter KJ,. Metabolism of androgens in the seminal vesicles and the different lobes of the prostate in young mature rats. J Steroid Biochem 1985; 22 (4): 513-519.
35. Matsui D, Sakari M, Sato T, Murayama A, Takada I, Kim M, Takeyama K, Kato S,. Transcriptional regulation of the mouse steroid 5alpha-reductase type II gene by progesterone in brain. Nucleic Acids Res 2002; 30 (6): 1387-1393.
36. Cunha GR, Chung LW,. Stromal-epithelial interactions-I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem 1981; 14 (12): 1317-1324.
37. Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, Cunha G,. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 2001; 229 (2): 432-442.
38. Yu S, Zhang C, Lin CC, Niu Y, Lai KP, Chang HC, Yeh SD, Chang C, Yeh S,. Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate 2011; 71 (5): 517-524.
39. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C,. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105 (34): 12182-12187.
40. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H, Chang C,. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008; 105 (34): 12188-12193.
41. Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC, Moses HL, Shyr CR, Chang C, Yeh S,. Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate 2012; 72 (4): 437-439.
42. Wang YZ, Wong YC,. Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998; 35 (3): 165-177.
43. Gustafsson JA,. Steroids and the scientist. Mol Endocrinol 2005; 19 (6): 1412-1417.
44. Weihua Z, Lathe R, Warner M, Gustafsson JA,. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99 (21): 13589-13594.
45. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA,. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001; 98 (11): 6330-6335.
46. Imamov O, Morani A, Shim G-J, Omoto Y, Thulin-Andersson C, Warner M, Gustafsson JA,. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. PNAS 2004; 101 (25): 9375-9380.
47. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ, Kropp BP, Penning TM, Lin HK,. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13 (1): 169-180.
48. Yang Q, Titus MA, Fung KM, Lin HK,. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: Implication of androgen-independent prostate cancer progression. J Cell Biochem 2008; 104 (5): 1612-1624.
49. Morimoto I, Edmiston A, Horton R,. Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia. J Clin Invest 1980; 66 (3): 612-615.
50. Russell DW, Wilson JD,. Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem 1994; 63: 25-61.
51. McNamara KM, Handelsman DJ, Simanainen U,. The mouse as a model to investigate sex steroid metabolism in the normal and pathological prostate. J Steroid Biochem Mol Biol 2012; 131 (3-5): 107-121.
52. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW,. Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 1994; 152 (2 Pt 1): 438-442.
53. Pelletier G,. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 223-228.
54. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, Chopin D, Raynaud JP, Martin PM,. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68 (5-6): 189-195.